Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Eleda Infra Services Group (“Eleda”) on the acquisition of FASAB Mark AB (“FASAB”).
Mandate

Vinge has advised Eleda Infra Services Group (“Eleda”) on the acquisition of FASAB Mark AB (“FASAB”).

January 13, 2021 Employment and Benefits EU, Competition and Regulatory Environmental Law M&A Intellectual Property Corporate Crime & Compliance Commercial Agreements

FASAB is a local leading supplier of infrastructure services in the northern part of Skåne with a main focus on construction work on behalf of public purchasers via framework agreements with a yearly sales around SEK 300 million. The company’s management team will continue in their respective operational management roles and become shareholders of the Eleda group.

Vinge’s team consisted primarily of partner Christina Kokko and associates Johanna Wiberg and Hanna Risberg (M&A), Isak Willborg (Agreements), Ebba Svenburg (Employment), Rebecka Weitzberg (Intellectual Property), Johan Cederblad and Frida Ställborn (Real Property & Environment), Johan Wahlbom and Joel Kokko (Competition), Tove Lövgren Frisk (Compliance) and Nathalie Hughes (VDR-assistant).

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025